Latest Tokyo Brief coverage on Oncolys BioPharma Inc., tracking filings, financial news, and market signals from Japan.
TSE:4588
Oncolys BioPharma began commercial sales of its OBP-301 oncolytic virus therapy on August 21, about two and a half months after Japan's health ministry approved it for esophageal cancer patients who cannot have curative surgery or chemoradiotherapy, with Fujifilm Toyama Chemical distributing it to hospitals.
Japan added Oncolys BioPharma's esophageal cancer cell therapy, development code OBP-301, to its national insurance price list at ¥3.1mn a unit, or ¥9.3mn per patient, with coverage starting August 13 and sales launching August 21 through Fujifilm Toyama Chemical.
Japan's health ministry has put the pricing of Oncolys BioPharma's newly approved esophageal cancer therapy on the agenda for the Chuikyo panel that deliberates national insurance drug prices, with the company still targeting a launch within the current fiscal year even as the earnings impact stays under review.